Iraklis Tsangaris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9285843/publications.pdf

Version: 2024-02-01

88 3,354 29 56
papers citations h-index g-index

88 88 88 4641
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. European Respiratory Journal, 2022, 59, 2102024.	6.7	57
2	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2102311.	6.7	124
3	Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Hellenic Journal of Cardiology, 2022, 64, 93-96.	1.0	7
4	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2022, 41, 971-981.	0.6	9
5	The impact of cardiovascular comorbidities associated with risk for left heart disease on idiopathic pulmonary arterial hypertension: Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Pulmonary Circulation, 2022, 12, .	1.7	4
6	Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2022, 12, 1238.	2.6	7
7	Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Critical Care, 2022, 26, .	5. 8	14
8	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
9	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
10	Use of IFN \hat{I}^3 /IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock. Frontiers in Immunology, 2021, 12, 607217.	4.8	15
11	The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension. Diagnostics, 2021, 11, 1200.	2.6	8
12	Epidemiology and Management of Chronic Thromboembolic Pulmonary Hypertension in Greece. Real-World Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Journal of Clinical Medicine, 2021, 10, 4547.	2.4	8
13	Soluble fms-like tyrosine kinase 1, placental growth factor and procalcitonin as biomarkers of gram-negative sepsis. Medicine (United States), 2021, 100, e27662.	1.0	O
14	Coagulation Profiles of Pulmonary Arterial Hypertension Patients, Assessed by Non-Conventional Hemostatic Tests and Markers of Platelet Activation and Endothelial Dysfunction. Diagnostics, 2020, 10, 758.	2.6	13
15	COVID-19 Infection-Related Coagulopathy and Viscoelastic Methods: A Paradigm for Their Clinical Utility in Critical Illness. Diagnostics, 2020, 10, 817.	2.6	19
16	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. Journal of Heart and Lung Transplantation, 2020, 39, 1435-1444.	0.6	104
17	The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy. Medicine (United States), 2020, 99, e23365.	1.0	24
18	Life-threatening antineutrophil cytoplasmic antibody–associated vasculitis after influenza A H1N1 infection requiring veno-venous extracorporeal membrane oxygenation. Perfusion (United Kingdom), 2020, 35, 546-549.	1.0	3

#	Article	IF	Citations
19	Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Diagnostics, 2020, 10, 49.	2.6	7
20	Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension. Platelets, 2019, 30, 646-651.	2.3	18
21	Epidemiology and initial management of pulmonary arterial hypertension: realâ€world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Pulmonary Circulation, 2019, 9, 1-12.	1.7	21
22	Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders. Shock, 2019, 52, 334-339.	2.1	21
23	A PATIENT WITH INFLUENZA A INFECTION AND ANCA-ASSOCIATED VASCULITIS. Chest, 2019, 156, A223.	0.8	0
24	The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. Critical Care, 2019, 23, 387.	5.8	63
25	Increases in inflammatory and CD14dim/CD16pos/CD45pos patrolling monocytes in sepsis: correlation with final outcome. Critical Care, 2018, 22, 56.	5.8	32
26	Pulmonary hypertension in patients with interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2018, 50, 38-46.	2.6	21
27	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. European Respiratory Journal, 2018, 52, 1800248.	6.7	61
28	Survival in medically treated chronic thromboembolic pulmonary hypertension patients. , 2018, , .		0
29	Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. Critical Care, 2017, 21, 48.	5.8	29
30	Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clinical Microbiology and Infection, 2017, 23, 104-109.	6.0	105
31	Survival after multiple traumas is associated with improved outcomes from gram-negative sepsis: Clinical and experimental evidence. Journal of Infection, 2017, 74, 163-171.	3.3	4
32	Angiopoietin-2 Levels as Predictors of Outcome in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome. Disease Markers, 2017, 2017, 1-6.	1.3	18
33	Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Medicine, 2017, 15, 172.	5.5	132
34	The evolving role of the renin–angiotensin system in ARDS. Critical Care, 2017, 21, 329.	5.8	9
35	Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment., 2017,,.		0
36	Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. , 2017, , .		0

#	Article	IF	CITATIONS
37	Metabolite Profiles in Sepsis: Developing Prognostic Tools Based on the Type of Infection*. Critical Care Medicine, 2016, 44, 1649-1662.	0.9	86
38	Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation. Medicine (United States), 2016, 95, e3037.	1.0	18
39	Individualized significance of the â^251 A/T single nucleotide polymorphism of interleukin-8 in severe infections. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 563-570.	2.9	13
40	Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clinical Microbiology and Infection, 2016, 22, 499-506.	6.0	38
41	Cardiovascular risk in pulmonary alveolar proteinosis. Expert Review of Respiratory Medicine, 2016, 10, 235-240.	2.5	2
42	Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis. BMC Immunology, 2014, 15, 585.	2.2	8
43	Clinical Usefulness of Novel Serum and Imaging Biomarkers in Risk Stratification of Patients with Stable Angina. Disease Markers, 2014, 2014, 1-14.	1.3	6
44	Improving Patient Care in Pulmonary Arterial Hypertension: Addressing Psychosocial Issues. Journal of Clinical Hypertension, 2014, 16, 159-161.	2.0	8
45	Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2014, 69, 1111-1118.	3.0	46
46	The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clinical Chemistry and Laboratory Medicine, 2014, 52, 937-50.	2.3	35
47	Polymicrobial bloodstream infections: Epidemiology and impact on mortality. Journal of Global Antimicrobial Resistance, 2013, 1, 207-212.	2.2	43
48	Preclinical Pulmonary Capillary Endothelial Dysfunction is Present in Brain Dead Subjects. Pulmonary Circulation, 2013, 3, 419-425.	1.7	5
49	The role of procalcitonin and IL-6 in discriminating between septic and non-septic causes of ALI/ARDS: a prospective observational study. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1535-42.	2.3	14
50	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically III Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2013, 57, 668-671.	3.2	71
51	Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Critical Care, 2013, 17, R247.	5.8	61
52	Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome. Minerva Anestesiologica, 2013, 79, 861-70.	1.0	17
53	Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism and circulating ACE levels are not associated with outcome in critically ill septic patients. Clinical Chemistry and Laboratory Medicine, 2012, 50, 293-9.	2.3	6
54	Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?. European Respiratory Journal, 2012, 40, 794-795.	6.7	8

#	Article	IF	CITATIONS
55	Pulmonary Hypertension in Parenchymal Lung Disease. Pulmonary Medicine, 2012, 2012, 1-14.	1.9	4
56	Gene Polymorphisms in the Heme Degradation Pathway and Outcome of Severe Human Sepsis. Shock, 2012, 38, 459-465.	2.1	17
57	Steroids in Idiopathic Pulmonary Fibrosis Acute Exacerbation: Defenders or Killers?. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 587-588.	5 . 6	27
58	Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. Blood, 2012, 120, 1531-1532.	1.4	21
59	Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Critical Care, 2012, 16, R149.	5.8	94
60	Red blood cell transfusion affects microdialysis-assessed interstitial lactate/pyruvate ratio in critically ill patients with late sepsis. Intensive Care Medicine, 2012, 38, 1843-1850.	8.2	23
61	Ovarian hyperstimulation syndrome complicated by severe communityâ€acquired pneumonia due to methicillinâ€resistant Staphylococcus aureus positive for Pantonâ€Valentine leukocidin. Journal of Obstetrics and Gynaecology Research, 2012, 38, 476-478.	1.3	2
62	Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. Journal of Hospital Infection, 2011, 77, 58-63.	2.9	45
63	TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infectious Diseases, 2011, 11, 309.	2.9	17
64	Life-threatening aortic thrombosis in a trauma patient homozygous for factor V Leiden mutation: Case report. Thrombosis Journal, 2011, 9, 8.	2.1	1
65	General Prognostic Scores in Outcome Prediction for Cancer Patients Admitted to the Intensive Care Unit. American Journal of Critical Care, 2011, 20, 56-66.	1.6	25
66	Kinetics of Adipose Tissue Microdialysis-Derived Metabolites in Critically III Septic Patients. Shock, 2011, 35, 343-348.	2.1	19
67	Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Critical Care Medicine, 2010, 38, 2229-2241.	0.9	240
68	ASSOCIATION OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION WITH ELEVATED NT-pro-BNP IN GENERAL INTENSIVE CARE UNIT PATIENTS WITH PRESERVED EJECTION FRACTION. Shock, 2010, 33, 141-148.	2.1	44
69	The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. Blood Coagulation and Fibrinolysis, 2010, 21, 175-181.	1.0	10
70	Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification. European Respiratory Journal, 2010, 35, 700-701.	6.7	3
71	Clinical review: Idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadne's thread. Critical Care, 2010, 14, 246.	5.8	60
72	Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infectious Diseases, 2009, 9, 213.	2.9	47

#	Article	IF	CITATIONS
73	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3430-3436.	3.2	448
74	Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Critical Care, 2009, 13, R172.	5.8	34
75	The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS. Thrombosis Research, 2009, 123, 832-836.	1.7	29
76	Acute Severe Asthma. Drugs, 2009, 69, 2363-2391.	10.9	41
77	Inhaled vasodilators for pulmonary hypertension in left heart disease: Should we start considering?*. Critical Care Medicine, 2009, 37, 1155-1156.	0.9	0
78	Impact of catheter-related bloodstream infections on the mortality of critically ill patients: A meta-analysis*. Critical Care Medicine, 2009, 37, 2283-2289.	0.9	129
79	The Effect of Plasma Homocysteine Levels on Clinical Outcomes of Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome. American Journal of the Medical Sciences, 2009, 338, 474-477.	1.1	5
80	PROGNOSTIC IMPORTANCE OF INCREASED PLASMA AMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVELS IN A LARGE NONCARDIAC, GENERAL INTENSIVE CARE UNIT POPULATION. Shock, 2009, 31, 342-347.	2.1	36
81	Do Not Forget Pulmonary Hypertension in Asplenic Patients. American Journal of Medicine, 2008, 121, e21.	1.5	0
82	Pituitary-adrenal responses following major abdominal surgery. Hormones, 2008, 7, 237-242.	1.9	20
83	Postobstructive Pulmonary Edema. Chest, 2007, 132, 2056.	0.8	2
84	The effect of exogenous surfactant in patients with lung contusions and acute lung injury. Intensive Care Medicine, 2007, 33, 851.	8.2	29
85	Bronchoalveolar lavage alterations during prolonged ventilation of patients without acute lung injury. European Respiratory Journal, 2003, 21, 495-501.	6.7	92
86	Effect of the Prone Position on Patients with Hydrostatic Pulmonary Edema Compared with Patients with Acute Respiratory Distress Syndrome and Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 360-368.	5.6	119
87	Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Intensive Care Medicine, 1998, 24, 296-303.	8.2	127
88	Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema American Journal of Respiratory and Critical Care Medicine, 1997, 155, 945-951.	5.6	66